JNJ vs RNA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
RNA exhibits critical financial distress, characterized by a Piotroski F-Score of 4/9 which barely maintains a 'stable' rating despite catastrophic liquidity metrics. The company is facing a severe solvency crisis with a Current Ratio of 0.07 and a negative Price/Book ratio of -3.57, indicating negative shareholders' equity. Revenue has collapsed by 71.10% YoY, and the company has missed earnings estimates in 100% of the last four quarters. Combined with aggressive insider selling by the CEO and CFO, the fundamental outlook is extremely poor.
Compare Another Pair
Related Comparisons
JNJ vs RNA: Head-to-Head Comparison
This page compares Johnson & Johnson (JNJ) and Atrium Therapeutics, Inc. (RNA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.